Cox regression analysis regarding the impact of CR evaluation on OS and RFS
. | Non-sCR vs sCR . | |
---|---|---|
HR . | 95% CI . | |
OS | ||
Crude | 1.41 | 1.17-1.69 |
Age and sex adjusted | 1.32 | 1.10-1.59 |
Fully adjusted* | 1.34 | 1.10-1.64 |
RFS | ||
Crude | 1.28 | 1.08-1.53 |
Age and sex adjusted | 1.23 | 1.03-1.47 |
Fully adjusted* | 1.25 | 1.03-1.51 |
. | Non-sCR vs sCR . | |
---|---|---|
HR . | 95% CI . | |
OS | ||
Crude | 1.41 | 1.17-1.69 |
Age and sex adjusted | 1.32 | 1.10-1.59 |
Fully adjusted* | 1.34 | 1.10-1.64 |
RFS | ||
Crude | 1.28 | 1.08-1.53 |
Age and sex adjusted | 1.23 | 1.03-1.47 |
Fully adjusted* | 1.25 | 1.03-1.51 |
Adjusted for age, sex, World Health Organization performance score at diagnosis, leukocyte count at diagnosis, CR as response after first or second induction therapy, and cytogenetic risk group.